https://www.selleckchem.com/pr....oducts/ici-118551-ic
The identification of early or primary resistance to androgen signaling inhibitors (ASIs) is of great value for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the predictive value of prostate-specific antigen (PSA) response at dour weeks of first-line ASIs treatment for mCRPC patients. A total of 254 patients treated with ASIs (abiraterone acetate AA and enzalutamide Enz) at the first-line treatment are retrospectively analyzed. Patients are stratified according to the achie
Like
Comment
Share
